BusinessChina Nuokang Bio-Pharma Falls on NY Debut
By wchung | 02 Jun, 2026
Shares of China Nuokang Bio-Pharmaceutical Inc. fell nearly 4 percent in their trading debut Thursday after pricing at $9 per American depositary share, below their expected range.
The China-based biopharmaceutical company, which specializes in blood and cardiovascular treatments, had expected the initial public offering of 5 million ADSs to price between $10 and $12.
The company said net proceeds from the offering totaled about $32.9 million. The company plans to use the funds to grow its sales and marketing platform, for new acquisitions, for research and to expand manufacturing facilities.
Shares, which trade under the symbol “NKBP” on the Nasdaq, fell 33 cents, or 3.7 percent, to close at $8.67 with about 2.3 million shares changing hands during the session.
12/10/2009 4:53 PM NEW YORK (AP)
Recent Articles
- Huang Anoints Marvell 'Next Trillion-Dollar Company'
- China Owns More Than 11,000 German-Developed Patents
- UN Warns World to Prepare for Extreme El Niño Heat Risk
- SK Hynix Plans to Double Wafer Capacity in Next Five Years
- Robot Patrol Dogs Coming to Taiwan's South China Sea Islands
- Futility of US Efforts to Ban AI Chip Exports to China Noted by Arm Holdings CEO
- China's Carmakers Keep Expanding Europe Footprint
- Amazon's Ring Sued over Facial Recognition Feature
- Tesla Extends Growth Surge of Chinese-Made EVs
- Sanjay Mehrotra's Chat with Jensen Huang Triggered Frugal Micron's Surge to $1 Trillion Club